Plecanatide

Plecanatide
Clinical data
Trade names	Trulance, Plectide
Other names	SP-304; H-Asn-Asp-Glu-Cys(1)-Glu-Leu-Cys(2)-Val-Asn-Val-Ala-Cys(1)-Thr-Gly-Cys(2)-Leu-OH
License data	US DailyMed: Plecanatide; US FDA: Plecanatide;
Routes of; administration	By mouth
ATC code	A06AX07 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only;
Identifiers
	IUPAC name L-Leucine, L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-cysteinyl-L-αglutamyl-L-leucyl-L-cysteinyl-L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cysteinyl-L-threonylglycyl-Lcysteinyl-, cyclic (4→12),(7→15)-bis(disulfide).;
CAS Number	467426-54-6 ;
PubChem CID	70693500;
IUPHAR/BPS	9069;
DrugBank	DB13170 ;
ChemSpider	28530494 ;
UNII	7IK8Z952OK;
KEGG	D09948 ;
ChEMBL	ChEMBL2103867 ;
CompTox Dashboard (EPA)	DTXSID60196933 ;
Chemical and physical data
Formula	C65H104N18O26S4
Molar mass	1681.89 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1C(=O)NC2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)CNC(=O)C(NC2=O)C(C)O)C(=O)NC(CC(C)C)C(=O)O)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)C(C)C)CC(=O)N)C(C)C)CC(C)C)CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(=O)N)N;
	InChI InChI=1S/C65H104N18O26S4/c1-25(2)15-34-55(98)80-41-24-113-110-21-38(58(101)77-37(65(108)109)16-26(3)4)71-44(87)20-69-62(105)50(30(10)84)83-61(104)40(78-51(94)29(9)70-63(106)48(27(5)6)81-57(100)35(18-43(68)86)76-64(107)49(28(7)8)82-60(41)103)23-112-111-22-39(59(102)73-32(53(96)75-34)11-13-45(88)89)79-54(97)33(12-14-46(90)91)72-56(99)36(19-47(92)93)74-52(95)31(66)17-42(67)85/h25-41,48-50,84H,11-24,66H2,1-10H3,(H2,67,85)(H2,68,86)(H,69,105)(H,70,106)(H,71,87)(H,72,99)(H,73,102)(H,74,95)(H,75,96)(H,76,107)(H,77,101)(H,78,94)(H,79,97)(H,80,98)(H,81,100)(H,82,103)(H,83,104)(H,88,89)(H,90,91)(H,92,93)(H,108,109)/t29-,30+,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,48-,49-,50-/m0/s1 ; Key:NSPHQWLKCGGCQR-DLJDZFDSSA-N ;

Plecanatide, sold under the brand name Trulance, is a medication for the treatment of chronic idiopathic constipation (CIC)^[3] and irritable bowel syndrome with constipation.^[4] It is available in India under the brand name Plectide (OQM Div, MSN Laboratories, India). Plecanatide is an agonist of guanylate cyclase-C. Plecanatide increases intestinal transit and fluid through a buildup of cGMP.^[5]^[6]

^ "Summary Basis of Decision (SBD) for Trulance". Health Canada. 23 October 2014. Retrieved 29 May 2022.
^ "TRULANCE (plecanatide) tablets, for oral use" (PDF). Synergy Pharmaceuticals Inc. U.S. Food and Drug Administration. January 2017. Archived from the original (PDF) on February 21, 2017.
^ "FDA approves Trulance for Chronic Idiopathic Constipation". FDA.gov. U.S. Food and Drug Administration. Archived from the original on January 20, 2017. Retrieved 20 January 2017.
^ Miner, Philip B (2020-02-01). "Plecanatide for the treatment of constipation-predominant irritable bowel syndrome". Expert Review of Gastroenterology & Hepatology. 14 (2): 71–84. doi:10.1080/17474124.2020.1722101. ISSN 1747-4124. PMID 31985305. S2CID 210922857.
^ "TRULANCE package insert" (PDF). Trulance website. Synergy Pharmaceuticals Inc. 420 Lexington Avenue, Suite 2012 New York, New York 10170. Retrieved 20 January 2017.
^ Thomas RH, Luthin DR (June 2015). "Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents". Pharmacotherapy. 35 (6): 613–30. doi:10.1002/phar.1594. PMID 26016701. S2CID 24825251.

[1] "Summary Basis of Decision (SBD) for Trulance". Health Canada. 23 October 2014. Retrieved 29 May 2022.

[2] "TRULANCE (plecanatide) tablets, for oral use" (PDF). Synergy Pharmaceuticals Inc. U.S. Food and Drug Administration. January 2017. Archived from the original (PDF) on February 21, 2017.

[FDA.gov-3] "FDA approves Trulance for Chronic Idiopathic Constipation". FDA.gov. U.S. Food and Drug Administration. Archived from the original on January 20, 2017. Retrieved 20 January 2017.

[Miner2020-4] Miner, Philip B (2020-02-01). "Plecanatide for the treatment of constipation-predominant irritable bowel syndrome". Expert Review of Gastroenterology & Hepatology. 14 (2): 71–84. doi:10.1080/17474124.2020.1722101. ISSN 1747-4124. PMID 31985305. S2CID 210922857.

[5] "TRULANCE package insert" (PDF). Trulance website. Synergy Pharmaceuticals Inc. 420 Lexington Avenue, Suite 2012 New York, New York 10170. Retrieved 20 January 2017.

[Review_article_2015-6] Thomas RH, Luthin DR (June 2015). "Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents". Pharmacotherapy. 35 (6): 613–30. doi:10.1002/phar.1594. PMID 26016701. S2CID 24825251.

[1]

[2]

[3]

[4]

[5]

[6]